KS SB250

Allows patients with life-threatening or severely debilitating illnesses to access individualized investigational treatments (including gene therapy and neoantigen vaccines) that are custom-made based on their genetic profile, after exhausting FDA-approved options

Requires written informed consent documenting the proposed treatment, potential outcomes including death, and patient financial liability for all treatment costs

Protects healthcare providers from license revocation or disciplinary action based solely on recommending individualized investigational treatments to eligible patients

Prohibits state officials from blocking eligible patient access and shields manufacturers and providers from private lawsuits if they comply in good faith with the act

Requires patient consent and profit-sharing agreements before any commercial application of products developed from a patient's biospecimen